Abstract
The genetic factors of stroke in South Asians are largely unexplored. Exome-wide sequencing and association analysis (ExWAS) in 75 K Pakistanis identified NM_000435.3(NOTCH3):c.3691C>T, encoding the missense amino acid substitution p.Arg1231Cys, enriched in South Asians (alternate allele frequency = 0.58% compared to 0.019% in Western Europeans), and associated with subcortical hemorrhagic stroke [odds ratio (OR) = 3.39, 95% confidence interval (CI) = [2.26, 5.10], p value = 3.87×10-9), and all strokes (OR [CI] = 2.30 [1.77, 3.01], p value = 7.79×10-10). NOTCH3 p.Arg231Cys was strongly associated with white matter hyperintensity on MRI in United Kingdom Biobank (UKB) participants (effect [95% CI] in SD units = 1.1 [0.61, 1.5], p value = 3.0×10-6). The variant is attributable for approximately 2.0% of hemorrhagic strokes and 1.1% of all strokes in South Asians. These findings highlight the value of diversity in genetic studies and have major implications for genomic medicine and therapeutic development in South Asian populations.
Competing Interest Statement
Funding. Fieldwork for this study was funded by the Center for Non-Communicable Diseases, Pakistan. DNA sequencing was funded by Regeneron Pharmaceuticals Inc. Employment. JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC, PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, ET, SC, TC are or were employees of Regeneron Genetics Center LLC or Regeneron Pharmaceuticals Inc. and contributed to this manuscript as part of their regular duties as salaried employees. AR, MJ, MZK, MRM, MBL, PF, and DS and SK are employees of the Center for Non-Communicable Disease and received salaried compensation for their contribution to this manuscript. Personal Financial Interests. JLRF, ARS, NB, DeS, MC, JO, JR, BY, MK, JB, GT, SG, TD, NV, LAL, AZ, NP, FS, JM, GC, PX, AB, SADG, HM, IT, KK, AE, DDA, SF, WL, TC are or were employees of Regeneron Genetics Center LLC or Regeneron Pharmaceuticals Inc. and received stock and stock options as part of their compensation as employees. JLRF, ARS, DS, AB, and SK are named inventors on patent pending US 20230000897A1 that discloses methods of treating subjects having a cerebrovascular disease by administering Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) agents, and methods of identifying subjects having an increased risk of developing a cerebrovascular disease.
Funding Statement
Fieldwork for this study was funded by the Center for Non-Communicable Diseases, Pakistan. DNA sequencing was funded by Regeneron Pharmaceuticals Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
PGR has received approval by the relevant research ethics committee of each of the institutions involved in participant recruitment, as well as centrally by the IRB board of the Center for Non-Communicable Diseases which is registered with the National Institutes of Health, USA. PGR has also been approved by the National Bioethics Committee, Islamabad Health Research Institute, National Institutes of Health of Pakistan.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Updated details of methods and data availability.